Compare CTW & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | CNTN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 178.5M |
| IPO Year | 2025 | 2021 |
| Metric | CTW | CNTN |
|---|---|---|
| Price | $1.75 | $1.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.8K | ★ 735.7K |
| Earning Date | 10-15-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.66 |
| 52 Week High | $3.14 | $5.27 |
| Indicator | CTW | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 42.22 |
| Support Level | $1.19 | $1.75 |
| Resistance Level | $1.88 | $2.40 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.48 | 27.07 |
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.